Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
Alliances with CVS Health and Javara further embed clinical research into the community healthcare setting, expanding access to patient populations across the U.S to increase diversity in clinical trials
Amarex Clinical Research guides its client to phase II of FDA trials
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Subscribe To Our Newsletter & Stay Updated
